LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

Rhea-AI Summary

LifeMD (NASDAQ: LFMD) expanded its collaboration with Novo Nordisk to offer Wegovy pill (oral semaglutide) through LifeMD’s telehealth and integrated NovoCare Pharmacy services. The U.S. FDA approved the Wegovy pill on Dec 22, 2025 as the first oral GLP-1 for chronic weight management and certain cardiovascular risk reduction. A 64-week Phase 3 trial showed 16.6% mean weight loss versus 2.7% for placebo. Eligible patients can access Wegovy pills via LifeMD starting at $149/month, with staged price increases effective Apr 15, 2026. LifeMD offers virtual visits, nationwide testing, clinical oversight, and home delivery across all 50 states.

Positive

• FDA approval of Wegovy pill on Dec 22, 2025
• Phase 3 mean weight loss of 16.6% versus 2.7%
• Cash-pay pricing as low as $149/month
• End-to-end telehealth and pharmacy across all 50 states

Negative

• Eligibility limited to uninsured or patients whose insurance does not cover weight-loss drugs
• Wegovy pill prices increase after Apr 15, 2026 to up to $299/month

Key Figures

Wegovy pill price: $149 per month Trial duration: 64 weeks Mean weight loss: 16.6% +5 more

8 metrics

Wegovy pill price $149 per month Eligible LifeMD patients cash-pay starting price

Trial duration 64 weeks Phase 3 Wegovy pill weight-loss trial

Mean weight loss 16.6% Once-daily Wegovy pill plus diet and exercise

Placebo weight loss 2.7% Placebo arm in 64-week Phase 3 trial

Lower-dose pills 1.5 mg and 4 mg Wegovy pill strengths at $149 per month

Higher-dose pills 9 mg and 25 mg Wegovy pill strengths at $299 per month after April 15, 2026

Mid-tier price $199 per month Wegovy 4 mg pill after April 15, 2026

High-tier price $299 per month Wegovy 9 mg and 25 mg pills after April 15, 2026

Market Reality Check

Price: $22.58 Vol: Volume 879,244 is 0.72x t...

normal vol

$22.58 Last Close

Volume Volume 879,244 is 0.72x the 20-day average, suggesting no outsized positioning pre-announcement. normal

Technical Shares at $3.49 are trading below the $7.40 200-day moving average, reflecting a longer-term downtrend.

Peers on Argus

Peers show mixed moves, with MNDR up 3.72% while HCAT, SLP, SOPH, and CCLD are d...

Peers show mixed moves, with MNDR up 3.72% while HCAT, SLP, SOPH, and CCLD are down between 0.34% and 4.6%, indicating stock-specific rather than broad sector momentum for LFMD.

Historical Context

5 past events · Latest: Dec 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 26	Preferred dividend	Neutral	-12.5%	Declared cash dividend on Series A preferred with set record and payment dates.
Nov 24	Awards & recognition	Positive	+3.1%	Recognition by Deloitte Fast 500 and TIME tied to revenue growth and stability.
Nov 17	Quarterly earnings	Positive	+2.2%	Reported Q3 revenue and EBITDA growth plus debt paydown and strong guidance.
Nov 17	GLP-1 partnership	Positive	+2.2%	Expanded Novo Nordisk collaboration with market-leading cash-pay GLP-1 pricing.
Nov 10	Conference participation	Neutral	-2.1%	Participation in BTIG forum on scalable virtual primary care and obesity platform.

Pattern Detected

Over the past few months, LFMD’s positive operational and partnership updates generally coincided with modest gains, while a preferred dividend headline saw a sharp decline, indicating selective investor enthusiasm by news type.

Recent Company History

Over the last several months, LifeMD reported stronger Q3 2025 results with rising revenue and adjusted EBITDA, announced expanded GLP-1 pricing collaborations with Novo Nordisk, and gained recognition on Deloitte’s Fast 500 and TIME’s growth list. It also declared a dividend on its 8.875% Series A preferred stock and participated in a digital health forum. Partnership and earnings items around GLP-1 and telehealth growth tended to align with positive share reactions, while the preferred dividend coincided with a double-digit percentage decline.

Market Pulse Summary

This announcement broadens LifeMD’s collaboration with Novo Nordisk by adding the FDA‑approved Wegov...

Analysis

This announcement broadens LifeMD’s collaboration with Novo Nordisk by adding the FDA‑approved Wegovy oral pill to its GLP‑1 portfolio at cash‑pay prices starting at $149 per month. It builds on earlier partnerships around Wegovy and Ozempic within LifeMD’s nationwide virtual care, diagnostics, and pharmacy infrastructure. In context of recent revenue growth and prior accounting adjustments, investors may watch uptake of oral GLP‑1s, pricing sustainability across dose tiers, execution of end‑to‑end logistics, and any further regulatory disclosures.

Key Terms

glp-1, semaglutide, phase 3, placebo, +4 more

8 terms

glp-1 medical

"first and only FDA-approved oral GLP-1 therapy for chronic weight management"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

semaglutide medical

"Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1"

Semaglutide is a medication originally developed to help manage blood sugar levels in people with diabetes, but it also promotes weight loss. It works by mimicking a natural hormone that helps control appetite and insulin release. For investors, its potential to influence healthcare and weight management markets makes it a significant product in the pharmaceutical industry.

phase 3 medical

"supported by a 64-week Phase 3 trial showing weight loss efficacy"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

placebo medical

"achieving 16.6% mean weight loss versus 2.7% with placebo."

A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.

telehealth technical

"through its end-to-end telehealth platform."

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

diagnostic testing medical

"access to nationwide diagnostic testing, coordinated pharmacy fulfillment"

Diagnostic testing is the use of medical tests—such as lab analyses, imaging scans, or rapid point-of-care assays—to detect, identify or monitor disease, infection, or other health indicators in people or samples. For investors it matters because demand, accuracy, regulatory approval, and reimbursement determine a test’s commercial value; think of it like a car’s diagnostic check that can detect problems early, influence repair choices, and drive how much people pay for the service.

cardiovascular events medical

"reduce the risk of certain major adverse cardiovascular events."

Cardiovascular events are serious problems involving the heart or blood vessels, such as heart attacks, strokes, heart failure or dangerous irregular heartbeats. Investors care because these events drive demand for treatments, shape outcomes in clinical trials, affect healthcare costs, and can change a company’s sales, legal risk or insurance losses — like warning lights on a car that signal expensive repairs or the need for new parts.

pharmacy fulfillment technical

"coordinated pharmacy fulfillment with fast shipping and real-time tracking"

Pharmacy fulfillment is the process of receiving, preparing, dispensing and delivering prescription medications and related products to patients or healthcare providers, often including insurance billing and tracking. For investors, it matters because efficient fulfillment reduces costs, speeds delivery, and improves customer retention—similar to a reliable delivery system for online orders—while poor fulfillment can lead to higher expenses, lost sales, regulatory risk, and damage to reputation.

AI-generated analysis. Not financial advice.

Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy^® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth platform. Eligible patients can access the Wegovy® pill for as little as $149 per month, further expanding LifeMD’s portfolio of branded obesity treatments.

This announcement broadens LifeMD’s long-standing collaboration with Novo Nordisk. As part of the relationship, LifeMD is featured on the NovoCare^® and Wegovy^® websites as a trusted telehealth provider, reflecting growing demand for convenient, clinically supported access to branded GLP-1 therapies.

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Wegovy^® pill as the first and only oral GLP-1 therapy indicated to reduce excess body weight, support long-term weight maintenance, and reduce the risk of certain major adverse cardiovascular events.¹ FDA approval of the Wegovy^® pill was supported by a 64-week Phase 3 trial showing weight loss efficacy unmatched by other oral GLP-1 candidates, with once-daily treatment plus diet and exercise achieving 16.6% mean weight loss versus 2.7% with placebo.² The availability of an oral formulation is expected to broaden access to GLP‑1 treatment by offering an alternative option for patients who may be hesitant to initiate or continue weekly injections.

“In close collaboration with Novo Nordisk, we moved quickly to bring the Wegovy^® pill to patients through LifeMD at the attractive cash-pay price, reinforcing our role as a preferred virtual destination for evidence-based medical weight management,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “We believe oral GLP-1 therapies represent an important next phase in obesity care. By supporting patients seeking care through Novo’s ‘Find a Doctor’ feature – alongside our own strong patient acquisition capabilities – we see a substantial long-term opportunity to further expand access and deliver a seamless experience that combines comprehensive clinical support with branded GLP-1 therapies shipped directly to patients’ homes.”

LifeMD’s integration with NovoCare^® Pharmacy provides streamlined access to Novo Nordisk’s FDA-approved GLP-1 medications, including Wegovy^® (injectable and oral) and Ozempic^®, at competitive cash-pay pricing. Patients receive a comprehensive, end-to-end experience that includes virtual visits with LifeMD’s affiliated medical group across all 50 states, ongoing clinical oversight, access to nationwide diagnostic testing, coordinated pharmacy fulfillment with fast shipping and real-time tracking, and simplified billing and payment.

“Innovation can only make a difference when people can access it. Our collaboration with LifeMD gives patients a trusted telehealth option where they can connect with a healthcare provider and begin authentic, FDA-approved treatment,” said Dave Moore, Executive Vice President, U.S. Operations, Novo Nordisk. “It’s another way we’re meeting people where they receive care and with the first and only FDA-approved oral GLP-1, Wegovy^® pill offers patients convenience and choice.”

All doses of the Wegovy^® pill are available by prescription to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications. Wegovy^® 1.5mg and 4mg pills are available to patients at $149 per month. After April 15, 2026, Wegovy^® 4mg pills will be available at $199 per month, and the 9mg and 25mg pills will be available at $299 per month.

¹ Wegovy prescribing information: https://www.novo-pi.com/wegovy.pdf 
² Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.

About LifeMD, Inc.

LifeMD^® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com  

Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com

FAQ

When did the FDA approve Wegovy pill for chronic weight management (LFMD)?

The FDA approved the Wegovy pill on Dec 22, 2025 as the first oral GLP-1 for weight management.

What clinical efficacy supported Wegovy pill availability through LifeMD (LFMD)?

A 64-week Phase 3 trial showed 16.6% mean weight loss with once-daily treatment versus 2.7% for placebo.

How much does Wegovy pill cost through LifeMD (LFMD) at launch?

Eligible patients can access Wegovy pills through LifeMD starting at $149 per month.

Will Wegovy pill pricing change after April 15, 2026 for LifeMD patients (LFMD)?

Yes. After Apr 15, 2026 prices rise: 4mg to $199/month, and 9mg/25mg to $299/month.

Who is eligible to receive Wegovy pill via LifeMD (LFMD)?

All doses are available by prescription to LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications.

What services does LifeMD (LFMD) provide with Wegovy pill fulfillment?

LifeMD offers virtual visits, ongoing clinical oversight, nationwide diagnostic testing, coordinated pharmacy fulfillment, fast shipping, and simplified billing.